Scynexis Stock Price

-0.22 (-3.14%)
Upgrade to Real-Time
Afterhours (Closed)


52 Week Range


Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Scynexis Inc SCYX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.22 -3.14% 6.79 17:56:24
Open Price Low Price High Price Close Price Prev Close
7.06 6.685 7.13 6.79 7.01
Bid Price Ask Price Spread News
6.83 6.85 0.02 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
1,215 184,480 $ 6.91 $ 1,275,593 298,200 0.6018 - 10.15
Last Trade Time Type Quantity Stock Price Currency
18:50:36 3 $ 6.80 USD

Scynexis Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 140.08M 20.63M 15.82M $ - $ - -5.40 -1.30
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 330.00k 2.00%

more financials information »

Scynexis News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical SCYX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week7.227.266.366.86263,111-0.43-5.96%
1 Month7.907.986.367.35310,310-1.11-14.05%
3 Months9.299.356.368.09395,788-2.50-26.91%
6 Months5.4610.155.307.88492,0611.3324.36%
1 Year0.87310.150.60185.08425,2055.92677.78%
3 Years1.2810.150.352.05618,7015.51430.47%
5 Years3.9110.150.352.21528,6992.8873.66%

Scynexis Description

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. It is engaged in developing a lead product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains.

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.